Business Wire

Sigfox and INDIGO® weel Join Forces to Promote 100% Connected Urban Mobility

12.7.2019 14:47:00 EEST | Business Wire | Press release

Share

Self-service bicycle fleet INDIGO® weel, a subsidiary of the INDIGO group, has been fitted with sensors, supported by Sigfox's 0G network, that can accurately pinpoint their location at any given time. As the number of shared vehicles in circulation increases, this integration of Sigfox technology will help to better protect the fleet from damage or theft.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190712005234/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Photo : INDIGO weel

The Sigfox solution offers multiple benefits for INDIGO® weel:

  • An easier customer journey: pinpointing the location of bicycles more accurately, in real-time, allows users of the service to locate bikes on the street faster and more easily;
  • Better protection against damage and theft due to a greater understanding of high-risk areas;
  • A reduction in repair costs thanks to reusable sensors that can easily be transferred from a damaged bike to a new one;
  • Flexible technology that can be used in other markets, if the INDIGO® weel service expands internationally, courtesy of Sigfox's global 0G network that spans some sixty countries;
  • Durable sensors that consume very little energy

Together, INDIGO® weel and Sigfox are providing a solution to the public that addresses a number of the current challenges facing mobility services. Population growth in cities, as well as increasing environmental awareness now requires us to reconsider the way we move around each day. Innovative private sector services are therefore needed, in order to be able to offer a wider range of mobility solutions to the public. These must, however, complement the existing public transport offering, with those in charge working closely with city authorities in metropolitan areas.

New mobility solutions have been changing the face of city centre travel in recent years, but in order to be fully effective, they still have to find their place in the landscape. In this new market, INDIGO® weel is positioning itself as an innovative brand, keen to constantly evolve and partner with other forward-thinking businesses to do that.

One example of this innovation prompts users to take a photo at the end of their bike rental period to certify that the vehicle is in good parking condition. Each photo is then processed by customer services and users who comply with national, local and ‘Our Service’ rules will gain access to more advantageous offers.

Any change involves some risks and challenges, but the association between Sigfox and INDIGO® weel is already reaping benefits. Since the fleet was equipped with connected sensors, improvements to the geolocation system has reduced bicycle damage by a factor of 4. In addition, bicycle repair/replacement is now also faster than in the past. These improvements benefit INDIGO® weel, but also, more broadly, the inhabitants of cities where the connected vehicles are available, providing them with a high quality, sustainable service.

Jean Gadrat, CEO of INDIGO® weel, explains: "Public stakeholders and users today want a wider range of mobility solutions at their disposal and innovation in the sector that will help shape the city of tomorrow. It is in this context that we enter the market as a private company, in order to provide citizens with a respectful, complementary offering. INDIGO® weel wants to be a responsible player in the urban mobility market. We work tirelessly to offer the best possible service to our customers and make our products more efficient, which is why we have chosen to embed Sigfox’s technology into the fleet. It allows us to strengthen the sustainability of our offering and fully integrate our vehicles into the urban ecosystem.”

Patrick Cason, General Manager at Sigfox France, said: "Through this collaboration, we are once again demonstrating the many ways in which our 0G network can be used to serve society. The challenges of mobility, especially in cities, are many and well known. Faced with increasingly populated cities and an environmental awareness that can no longer be ignored, we must create new, more sustainable mobility solutions. Free floating bike is one of them. We are working with INDIGO® weel to provide the best service possible to meet the needs of citizens and to ensure that free floating bike finds its place in the city.”

About Sigfox
Sigfox is the initiator of the 0G network and the world’s leading IoT (Internet of Things) service provider. Its global network allows billions of devices to connect to the Internet, in a straightforward way, while consuming as little energy as possible. Sigfox unique approach to device-to-cloud communications addresses the three greatest barriers to global IoT adoption: cost, energy consumption and global scalability.

Today, the network is available in 60 countries, with 1 billion people covered. ISO 9001 certified and surrounded by a large ecosystem of partners and IoT key players, Sigfox empowers companies to move their business model towards more digital services, in key areas such as Asset Tracking and Supply Chain. Founded in 2010 by Ludovic Le Moan and Christophe Fourtet, the company is headquartered in France and has offices in Madrid, Munich, Boston, Dallas, San Jose, Dubai, Singapore, Sao Paulo and Tokyo.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press:
Sigfox
Antoine Mège, PR & Content Manager
antoine.mege@sigfox.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye